NO20050528L - Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft - Google Patents

Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft

Info

Publication number
NO20050528L
NO20050528L NO20050528A NO20050528A NO20050528L NO 20050528 L NO20050528 L NO 20050528L NO 20050528 A NO20050528 A NO 20050528A NO 20050528 A NO20050528 A NO 20050528A NO 20050528 L NO20050528 L NO 20050528L
Authority
NO
Norway
Prior art keywords
combination
cancer
treatment
tyrosine kinase
kinase inhibitors
Prior art date
Application number
NO20050528A
Other languages
English (en)
Norwegian (no)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20050528L publication Critical patent/NO20050528L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20050528A 2002-08-09 2005-01-31 Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft NO20050528L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0218526.2A GB0218526D0 (en) 2002-08-09 2002-08-09 Combination therapy
PCT/GB2003/003390 WO2004014426A1 (en) 2002-08-09 2003-08-05 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Publications (1)

Publication Number Publication Date
NO20050528L true NO20050528L (no) 2005-05-03

Family

ID=9942013

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050528A NO20050528L (no) 2002-08-09 2005-01-31 Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft

Country Status (14)

Country Link
US (2) US20050245549A1 (de)
EP (1) EP1534338A1 (de)
JP (1) JP2006500346A (de)
KR (1) KR20050059060A (de)
CN (1) CN100556456C (de)
BR (1) BR0313117A (de)
CA (1) CA2495489A1 (de)
GB (1) GB0218526D0 (de)
IL (1) IL166625A0 (de)
MX (1) MXPA05001457A (de)
NO (1) NO20050528L (de)
NZ (1) NZ537754A (de)
WO (1) WO2004014426A1 (de)
ZA (1) ZA200501061B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2306306T3 (es) 1999-11-05 2008-11-01 Astrazeneca Ab Nuevos derivados de quinazolina.
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
KR101089462B1 (ko) 2002-11-04 2011-12-07 아스트라제네카 아베 Ｓｒｃ 티로신 키나제 억제제로서의 퀴나졸린 유도체
CA2514227C (en) * 2003-02-13 2011-08-09 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
KR20120093411A (ko) * 2003-07-10 2012-08-22 아스트라제네카 아베 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도
AU2005288737B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Combination comprising ZD6474 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
BRPI0610574A2 (pt) * 2005-04-14 2010-07-06 Wyeth Corp uso de um inibidor de quinase para receptor do fator de crescimento epidérmico (egfr) em pacientes resistentes a gefitinib
JP2009502960A (ja) * 2005-07-27 2009-01-29 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
EP3173084B1 (de) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Chinazolinderivate zur behandlung von krebserkrankungen
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
CA2663599A1 (en) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
JP2010504949A (ja) * 2006-09-29 2010-02-18 アストラゼネカ アクチボラグ Ｚｄ６４７４とベバシズマブの癌療法のための組合せ
EP2451445B1 (de) 2009-07-06 2019-04-03 Boehringer Ingelheim International GmbH Verfahren zur trocknung von bibw2992, seiner salze und fester pharmazeutischer formulierungen mit diesem wirkstoff
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
GB201516905D0 (en) * 2015-09-24 2015-11-11 Stratified Medical Ltd Treatment of Neurodegenerative diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
DE60130017T2 (de) * 2000-11-22 2008-05-15 Novartis Ag Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
ES2280735T3 (es) * 2002-04-16 2007-09-16 Astrazeneca Ab Terapia de combinacion para el tratamiento de cancer.
WO2004014383A1 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
CA2514227C (en) * 2003-02-13 2011-08-09 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
KR20120093411A (ko) * 2003-07-10 2012-08-22 아스트라제네카 아베 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
AU2005288737B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Combination comprising ZD6474 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed

Also Published As

Publication number Publication date
CN100556456C (zh) 2009-11-04
US20050245549A1 (en) 2005-11-03
EP1534338A1 (de) 2005-06-01
ZA200501061B (en) 2007-01-31
CA2495489A1 (en) 2004-02-19
MXPA05001457A (es) 2005-06-06
US20100130493A1 (en) 2010-05-27
IL166625A0 (en) 2006-01-15
NZ537754A (en) 2008-02-29
CN1674938A (zh) 2005-09-28
BR0313117A (pt) 2005-07-05
GB0218526D0 (en) 2002-09-18
JP2006500346A (ja) 2006-01-05
KR20050059060A (ko) 2005-06-17
WO2004014426A1 (en) 2004-02-19
AU2003252976A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
BRPI0622054B8 (pt) composto e composição farmacêutica
NO20066056L (no) Behandling med Gemcitabin og en EGFR-inhibitor
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20066054L (no) behandling med cisplatin og en EGFR-inhibitor
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
MX2017013142A (es) Terapia combinada para tratar cáncer.
NO20053649D0 (no) Kombinasjonsterapi
NO20066080L (no) Behandling med irinotecan (CPT-11) og en AGFR-inhibitor
ATE500832T1 (de) Kombination von zd6474 und pemetrexed
NO20064753L (no) Kombinasjonsterapi
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
NO20064755L (no) Kombinasjonsterapi
EA200501166A1 (ru) Составы и способы лечения тромбоцитемии
NO20044498L (no) Kombinasjonsterapi for behandling av cancer
NO20064754L (no) Kombinasjonsterapi
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application